Simon

Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia. 

Read the supplement and earn CME credit for your knowledge of the following:

• The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
• The underrecognition and undertreatment of dyspareunia due to VVA.
• Efficacy results of randomized placebo controlled trials of ospemifene.
• Adverse events associated with ospemifene.
• Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.

Click on the image above or here to read the supplement and earn credit

Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia. 

Read the supplement and earn CME credit for your knowledge of the following:

• The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
• The underrecognition and undertreatment of dyspareunia due to VVA.
• Efficacy results of randomized placebo controlled trials of ospemifene.
• Adverse events associated with ospemifene.
• Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.

Click on the image above or here to read the supplement and earn credit

Estrogen and androgen deficiency from menopause causes vulvovaginal and urogenital changes and a plethora of symptoms, most prominently dyspareunia. 

Read the supplement and earn CME credit for your knowledge of the following:

• The pathophysiology of dyspareunia due to vulvovaginal atrophy (VVA) of menopause.
• The underrecognition and undertreatment of dyspareunia due to VVA.
• Efficacy results of randomized placebo controlled trials of ospemifene.
• Adverse events associated with ospemifene.
• Safety data of ospemifine as well as other oral selective estrogen receptor modulators and estrogens.

Click on the image above or here to read the supplement and earn credit